These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21917774)

  • 1. Levodopa toxicity and Parkinson disease: still a need for equipoise.
    Olanow CW; Obeso JA
    Neurology; 2011 Oct; 77(15):1416-7. PubMed ID: 21917774
    [No Abstract]   [Full Text] [Related]  

  • 2. Editor's note: does levodopa accelerate the pathologic process in Parkinson disease brain?
    Neurology; 2011 Oct; 77(15):1421. PubMed ID: 21917765
    [No Abstract]   [Full Text] [Related]  

  • 3. Is levodopa toxic? Insights from a brain bank.
    LeWitt PA; Dubow J; Singer C
    Neurology; 2011 Oct; 77(15):1414-5. PubMed ID: 21917780
    [No Abstract]   [Full Text] [Related]  

  • 4. Does levodopa accelerate the pathologic process in Parkinson disease brain?
    Parkkinen L; O'Sullivan SS; Kuoppamäki M; Collins C; Kallis C; Holton JL; Williams DR; Revesz T; Lees AJ
    Neurology; 2011 Oct; 77(15):1420-6. PubMed ID: 21917769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa gains psychostimulant-like properties after nigral dopaminergic loss.
    Engeln M; Fasano S; Ahmed SH; Cador M; Baekelandt V; Bezard E; Fernagut PO
    Ann Neurol; 2013 Jul; 74(1):140-4. PubMed ID: 23494678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?
    Ziv I; Zilkha-Falb R; Offen D; Shirvan A; Barzilai A; Melamed E
    Mov Disord; 1997 Jan; 12(1):17-23. PubMed ID: 8990049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normal substantia nigra patients treated with levodopa - Clinical, therapeutic and pathological observations.
    Rajput AH; Rajput ML; Robinson CA; Rajput A
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1232-7. PubMed ID: 26372624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurophysiology: stressful pacemaking.
    Bean BP
    Nature; 2007 Jun; 447(7148):1059-60. PubMed ID: 17597746
    [No Abstract]   [Full Text] [Related]  

  • 10. Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway.
    Booij J; Berendse HW
    J Neurol Sci; 2011 Nov; 310(1-2):40-3. PubMed ID: 21840542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed early morning turn "ON" in response to a single dose of levodopa in advanced Parkinson's disease: pharmacokinetics should be considered.
    Chaná P; Kuntsmann C; Reyes-Parada M; Sáez-Briones P
    J Neurol Neurosurg Psychiatry; 2004 Dec; 75(12):1782-3. PubMed ID: 15548507
    [No Abstract]   [Full Text] [Related]  

  • 12. Does levodopa affect metaiodobenzylguanidine myocardial accumulation in Parkinson's disease?
    Kishi M; Sakakibara R; Terada H; Ogawa E; Tateno T
    Mov Disord; 2011 Feb; 26(3):563-4. PubMed ID: 21287597
    [No Abstract]   [Full Text] [Related]  

  • 13. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
    Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease without expected neuropathologic abnormality.
    Velickovic M; Lesser G; Purohit D; Neufeld RR; Tarshish CY; Libow LS
    J Am Med Dir Assoc; 2004; 5(6):407-9. PubMed ID: 15530180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental study on inhibition of neuronal toxical effect of levodopa by ginkgo biloba extract on Parkinson disease in rats.
    Cao F; Sun S; Tong ET
    J Huazhong Univ Sci Technolog Med Sci; 2003; 23(2):151-3. PubMed ID: 12973934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemiparkinsonism and levodopa-induced dyskinesias following focal nigral lesion.
    Alves R; Barbosa E; Scaff M
    Mov Disord; 2006 Dec; 21(12):2267-8; author reply 2268. PubMed ID: 17078068
    [No Abstract]   [Full Text] [Related]  

  • 17. New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.
    Shan S; Hong-Min T; Yi F; Jun-Peng G; Yue F; Yan-Hong T; Yun-Ke Y; Wen-Wei L; Xiang-Yu W; Jun M; Guo-Hua W; Ya-Ling H; Hua-Wei L; Ding-Fang C
    Neurobiol Aging; 2011 Mar; 32(3):443-58. PubMed ID: 19368990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
    Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No].
    Friedman A
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S10-3. PubMed ID: 17941453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion.
    Růzicka E; Urgosík D; Jech R; Roth J; Vymazal J; Mecír P; Vladyka V
    Mov Disord; 2005 Jun; 20(6):759-62. PubMed ID: 15782419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.